Association analysis of ERCC5 gene polymorphisms with risk of breast cancer in Han women of northwest China

Breast Cancer

Volumn 23, Issue 3, 2016, Pages 479-485

  Wang, Haitao ^a   Wang, Tao ^a   Guo, Hongyun ^a   Zhu, Gongjian ^a   Yang, Suisheng ^a   Hu, Qingrong ^a   Du, Yanze ^a   Bai, Xiaorong ^a   Chen, Xuezhong ^a   Su, Haixiang ^a  

^a Gansu Provincial Academy of Medical Sciences and Gansu Provincial Cancer Hospital   (China)

Author keywords

Breast cancer; ERCC5; Single nucleotide polymorphism

Indexed keywords

CANNABINOID 2 RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; DNA BINDING PROTEIN; DNA EXCISION REPAIR PROTEIN ERCC-5; ENDONUCLEASE; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINA; CLINICAL FEATURE; CONTROLLED STUDY; DNA REPAIR; DOMINANT MODEL; ERCC5 GENE; EXON; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC VARIABILITY; GENOTYPE; HAN CHINESE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MUTATIONAL ANALYSIS; NON SYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISM; PRIORITY JOURNAL; PROMOTER REGION; RECESSIVE MODEL; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR IMMUNITY; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; POPULATION GENETICS;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHINA; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION FACTORS;

EID: 84961386588     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-015-0590-2     Document Type: Article

References (24)

1. Lacey JV Jr, Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen. 2002;39:82–8.
2. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468:98–102.
3. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447:1087–93.
4. Zhao E, Cui D, Yuan L, Lu W. MDM2 SNP 309 polymorphism and breast cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:3471–7.
5. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res. 2005;577:275–83.
6. Wood RD. DNA damage recognition during nucleotide excision repair in mammalian cells. Biochimie. 1999;81:39–44.
7. Wakasugi M, Reardon JT, Sancar A. The non-catalytic function of XPG protein during dual incision in human nucleotide excision repair. J Biol Chem. 1997;272:16030–4.
8. O’Donovan A, Davies AA, Moggs JG, West SC, Wood RD. XPG endonuclease makes the 3′ incision in human DNA nucleotide excision repair. Nature. 1994;371:432–5.
9. Emmert S, Schneider TD, Khan SG, Kraemer KH. The human XPG gene: gene architecture, alternative splicing and single nucleotide polymorphisms. Nucleic Acids Res. 2001;29:1443–52.
10. Hohl M, Dunand-Sauthier I, Staresincic L, Jaquier-Gubler P, Thorel F, Modesti M, et al. Domain swapping between FEN-1 and XPG defines regions in XPG that mediate nucleotide excision repair activity and substrate specificity. Nucleic Acids Res. 2007;35:3053–63.
11. Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, et al. ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol. 2008;26:2952–8.
12. Stevens EV, Nishizuka S, Antony S, Reimers M, Varma S, Young L, et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther. 2008;7:10–8.
13. Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer. 2002;94:393–7.
14. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998;58:604–8.
15. Mohrenweiser HW, Xi T, Vázquez-Matías J, Jones IM. Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol Biomarkers Prev. 2002;11:1054–64.
16. Bernig T, Chanock SJ. Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Rev Mol Diagn. 2006;6:319–31.
17. Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, Davico L, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case–control study. Int J Cancer. 2001;92:562–7.
18. Snoussi K, Mahfoudh W, Bouaouina N, Fekih M, Khairi H, Helal AN, et al. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer. 2010;10:283.
19. Blomquist TM, Crawford EL, Willey JC. Cis-acting genetic variation at an E2F1/YY1 response site and putative p53 site is associated with altered allele-specific expression of ERCC5 (XPG) transcript in normal human bronchial epithelium. Carcinogenesis. 2010;31:1242–50.
20. Fagbemi AF, Orelli B, Schärer OD. Regulation of endonuclease activity in human nucleotide excision repair. DNA Repair. 2011;10:722–9.
21. Ding DP, He XF, Zhang Y. Lack of association between XPG Asp1104His and XPF Arg415Gln polymorphism and breast cancer risk: a meta-analysis of case–control studies. Breast Cancer Res Treat. 2011;129:203–9.
22. Cheng L, Spitz MR, Hong WK, Wei Q. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case–control analysis. Carcinogenesis. 2000;21:1527–30.
23. Vodicka P, Stetina R, Polakova V, Tulupova E, Naccarati A, Vodickova L, et al. Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis. 2007;28:657–64.
24. Friedberg EC. DNA damage and repair. Nature. 2003;421:436–40.